Kunming Children's Hospital, Kunming, Yunnan, People's Republic of China.
Kunming University of Science and Technology, Kunming, Yunnan, People's Republic of China.
BMC Infect Dis. 2021 Aug 4;21(1):751. doi: 10.1186/s12879-021-06462-4.
Since 2016, enterovirus 71 (EV71) vaccines have been approved for market entry, and little is known about how the epidemiology of hand, foot, and mouth disease (HFMD) has been affected by the introduction of the vaccines in Yunnan Province. The study describes the epidemiological characteristics of HFMD before and after the introduction of EV71 vaccination in Yunnan Province.
Surveillance data collected between 2008 and 2019 were analyzed to produce epidemiological distribution on cases, etiologic composition, and EV71 vaccination coverage, as well as to compare these characteristics before and after EV71 vaccination.
A total of 1,653,533 children received EV71 vaccines from 2016 through 2019 in Yunnan. The annual EV71 vaccination coverage rate ranged from 5.53 to 15.01% among children ≤5 years old. After the introduction of EV71 vaccines, the overall incidence of HFMD increased and reached over 200 cases per 100,000 population-years in 2018 and 2019. However, the case severity and case fatality rate decreased and remained lower than 1 and 0.005% after 2016, respectively. EV71-associated mild, severe and fatal cases sharply decreased. The predominant viral serotype changed to non-EV71/non-CV-A16 enteroviruses which were detected across the whole province.
Non-EV71/non-CV-A16 enteroviruses became the predominant strain and led to a higher incidence in Yunnan. Expanding EV71 vaccination and strengthening laboratory-based surveillance could further decrease the burden of severe HFMD and detect and monitor emerging enteroviruses.
自 2016 年以来,肠道病毒 71 型(EV71)疫苗已获准上市,而对于云南省引入 EV71 疫苗后手足口病(HFMD)的流行病学情况知之甚少。本研究描述了云南省引入 EV71 疫苗前后 HFMD 的流行病学特征。
分析了 2008 年至 2019 年收集的监测数据,以产生病例的流行病学分布、病因构成和 EV71 疫苗接种覆盖率,并比较引入 EV71 疫苗前后的这些特征。
2016 年至 2019 年,云南省共有 1653533 名儿童接种了 EV71 疫苗。5 岁以下儿童的年 EV71 疫苗接种率范围为 5.53%至 15.01%。引入 EV71 疫苗后,HFMD 的总发病率增加,2018 年和 2019 年达到每 10 万人年超过 200 例。然而,自 2016 年以来,病例严重程度和病死率分别持续下降并保持在 1%和 0.005%以下。EV71 相关的轻症、重症和死亡病例急剧减少。主要病毒血清型转变为全省检测到的非 EV71/非 CV-A16 肠道病毒。
非 EV71/非 CV-A16 肠道病毒成为主要流行株,导致云南省发病率升高。扩大 EV71 疫苗接种和加强基于实验室的监测可以进一步降低重症 HFMD 的负担,并发现和监测新出现的肠道病毒。